Hepatitis B and Delta Virus Infections: Mechanistic Insights and Clinical Drug Therapy

Dear Colleagues,

Despite the availability of an effective prophylactic vaccine, Hepatitis B Virus (HBV) infection remains a considerable global health issue. As reported by the World Health Organization (WHO), approximately 300 million individuals are chronically infected with the HBV virus. Among them, an estimated 5% are coinfected with Hepatitis Delta Virus (HDV), although this figure is likely underestimated owing to limited routine screening and diagnostic challenges. HDV coinfection is associated with a more severe clinical course, resulting in a more rapid progression to cirrhosis, liver failure, and a markedly increased risk of hepatocellular carcinoma (HCC) compared to HBV monoinfection.

A comprehensive understanding of the molecular mechanisms underlying HBV and HDV replication is essential for identifying novel therapeutic targets. Recent years have seen considerable progress in the development of antiviral agents, including entry inhibitors for HDV and immunomodulatory strategies. Nonetheless, attaining a functional or sterilizing cure for chronic HBV infection remains a significant unmet challenge.

This Special Issue aims to compile high-quality original research articles and authoritative reviews focusing on the mechanistic insights and clinical drug therapy of HBV and HDV infections. Relevant topics include, but are not limited to, immune responses, innovative treatment strategies, and precision medicine approaches.

Through the integration of fundamental, translational, and clinical research, this Special Issue aims to provide a comprehensive and current perspective on the current landscape and future trajectories in the management of HBV and HDV infections.

Dr. Daniele Lombardo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.